[Treatment of male immune infertility by traditional Chinese medicine: A meta-analysis].

Q4 Medicine
中华男科学杂志 Pub Date : 2024-06-01
Chun-Mei Fan, Si-Qi Ma, Ke-Fan Ding, Yi-Jian Yang, Xin-Bang Wen, Zi-Qin Zhao, Shu-Hui Chen, Guo-Zheng Qin
{"title":"[Treatment of male immune infertility by traditional Chinese medicine: A meta-analysis].","authors":"Chun-Mei Fan, Si-Qi Ma, Ke-Fan Ding, Yi-Jian Yang, Xin-Bang Wen, Zi-Qin Zhao, Shu-Hui Chen, Guo-Zheng Qin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of traditional Chinese medicine (TCM) in the treatment of male immune infertility (MII) by meta-analysis.</p><p><strong>Methods: </strong>We retrieved randomized controlled trial (RCT) on the treatment of male immune infertility with traditional Chinese medicine from the databases of WanFang, Chinese Biomedical Literature, Cochrane Library, Weipu, PubMed and CNKI, and performed methodological quality assessment of the RCTs identified and statistical analysis and evaluation of the publication bias using the RevMan5.4 software.</p><p><strong>Results: </strong>Totally, 25 RCTs (2 563 cases) were included in this study. Compared with Western medicine alone in the treatment of MII, TCM achieved a significantly higher total effectiveness rate (OR = 6.35, 95% CI: 4.96-8.13, P<0.000 01), negative conversion rate of seminal plasma anti-sperm antibodies (OR = 4.52, 95% CI: 2.72 - 7.51, P<0.000 01), negative rate of serum anti-sperm antibodies (OR = 2.98, 95% CI: 2.23-3.96, P<0.000 01), sperm concentration (MD = 15.56, 95% CI: 11.32-19.79, P<0.000 01), grade a sperm motility (MD = 3.85, 95% CI: 1.91-5.79, P=0.000 01), grade a+b sperm motility (MD = 13.77, 95% CI: 7.06-20.48, P<0.000 1), sperm viability (MD = 10.32, 95% CI: 6.78-13.86, P<0.000 01) and pregnancy rate (OR = 3.53, 95% CI: 2.68-4.63, P<0.000 01), but a lower rate of adverse reactions (OR = 0.06, 95% CI: 0.01-0.23, P<0.000 01). There was no statistically significant difference in the percentage of morphologically abnormal sperm between TCM and Western medicine alone in the treatment of MII (MD = -7.53, 95% CI: -15.50-0.44, P = 0.06).</p><p><strong>Conclusion: </strong>TCM has a definite effectiveness and high safe in the treatment of male immune infertility.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"30 6","pages":"547-563"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华男科学杂志","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of traditional Chinese medicine (TCM) in the treatment of male immune infertility (MII) by meta-analysis.

Methods: We retrieved randomized controlled trial (RCT) on the treatment of male immune infertility with traditional Chinese medicine from the databases of WanFang, Chinese Biomedical Literature, Cochrane Library, Weipu, PubMed and CNKI, and performed methodological quality assessment of the RCTs identified and statistical analysis and evaluation of the publication bias using the RevMan5.4 software.

Results: Totally, 25 RCTs (2 563 cases) were included in this study. Compared with Western medicine alone in the treatment of MII, TCM achieved a significantly higher total effectiveness rate (OR = 6.35, 95% CI: 4.96-8.13, P<0.000 01), negative conversion rate of seminal plasma anti-sperm antibodies (OR = 4.52, 95% CI: 2.72 - 7.51, P<0.000 01), negative rate of serum anti-sperm antibodies (OR = 2.98, 95% CI: 2.23-3.96, P<0.000 01), sperm concentration (MD = 15.56, 95% CI: 11.32-19.79, P<0.000 01), grade a sperm motility (MD = 3.85, 95% CI: 1.91-5.79, P=0.000 01), grade a+b sperm motility (MD = 13.77, 95% CI: 7.06-20.48, P<0.000 1), sperm viability (MD = 10.32, 95% CI: 6.78-13.86, P<0.000 01) and pregnancy rate (OR = 3.53, 95% CI: 2.68-4.63, P<0.000 01), but a lower rate of adverse reactions (OR = 0.06, 95% CI: 0.01-0.23, P<0.000 01). There was no statistically significant difference in the percentage of morphologically abnormal sperm between TCM and Western medicine alone in the treatment of MII (MD = -7.53, 95% CI: -15.50-0.44, P = 0.06).

Conclusion: TCM has a definite effectiveness and high safe in the treatment of male immune infertility.

[中药治疗男性免疫性不育:荟萃分析]。
目的:通过荟萃分析评估中药治疗男性免疫性不育症(MII)的有效性和安全性:通过荟萃分析评价中药治疗男性免疫性不育症(MII)的有效性和安全性:方法:从万方数据库、中国生物医学文献数据库、Cochrane图书馆、维普数据库、PubMed数据库和CNKI数据库中检索中药治疗男性免疫性不育的随机对照试验(RCT),使用RevMan5.4软件对RCT进行方法学质量评估、统计分析和发表偏倚评价:结果:本研究共纳入25项RCT(2 563例)。与单纯西药治疗 MII 相比,中医药的总有效率明显更高(OR = 6.35,95% CI:4.96-8.13,PConclusion):中医治疗男性免疫性不育疗效确切,安全性高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中华男科学杂志
中华男科学杂志 Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
5367
期刊介绍: National journal of andrology was founded in June 1995. It is a core journal of andrology and reproductive medicine, published monthly, and is publicly distributed at home and abroad. The main columns include expert talks, monographs (basic research, clinical research, evidence-based medicine, traditional Chinese medicine), reviews, clinical experience exchanges, case reports, etc. Priority is given to various fund-funded projects, especially the 12th Five-Year National Support Plan and the National Natural Science Foundation funded projects. This journal is included in about 20 domestic databases, including the National Science and Technology Paper Statistical Source Journal (China Science and Technology Core Journal), the Source Journal of the China Science Citation Database, the Statistical Source Journal of the China Academic Journal Comprehensive Evaluation Database (CAJCED), the Full-text Collection Journal of the China Journal Full-text Database (CJFD), the Overview of the Chinese Core Journals (2017 Edition), and the Source Journal of the Top Academic Papers of China's Fine Science and Technology Journals (F5000). It has been included in the full text of the American Chemical Abstracts, the American MEDLINE, the American EBSCO, and the database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信